Highest-materiality recent filing
TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M
Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M
Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
TriSalus prices $40M public offering of 9.76M shares at $4.10/share
Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).
TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M
Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.
Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.
TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M
Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.
TriSalus completes Preferred Stock exchange; 98.82% tendered at 3.3 common shares each
Approximately 98.82% of outstanding Series A Convertible Preferred Stock (3,551,502 shares) validly tendered in exchange offer.
TriSalus launches exchange offer for Series A Preferred, up to 11.9M common shares
Offers up to 11,860,206 common shares in exchange for each share of Series A Convertible Preferred at $4.00 per share based on liquidation preference plus accrued dividends through Aug 10, 2027.
TriSalus Q1 rev $9.2M (+42% YoY); revises 2025 guidance: 50% growth, no adj. EBITDA positive
Net sales $9.2M, up 42% YoY and 11% sequential; gross margin 84% vs 85%.
TriSalus announces $22M private placement, Q1 revenue up 42% to $9.2M
Private placement of 5.5M shares at $4.00/share raises ~$22M gross; led by Nantahala Capital, Broadfin Holdings. Expected close May 2, 2025.
TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors
Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.
TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025
Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.
TriSalus promotes James Young to CFO; appoints new CCO and Chief of Clinical Operations
James Young promoted to CFO, effective Jan 6, 2025; annual base salary $420k, target bonus 50%.
TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025
Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.
TriSalus: Director Anil Singhal resigns; CMO Steven Katz departs
Director Anil Singhal resigned from Board, Compensation and Science/Technology committees effective Oct 28, 2024; no disagreement.
TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed
Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.
TriSalus completes warrant exchange; 78.9% of public warrants tendered; warrant amendment enacted
6,533,614 Public Warrants (78.89%) tendered for 0.30 shares each; settlement by July 1, 2024.
TriSalus launches warrant exchange offer at 0.3 shares per warrant; seeks to reduce dilution
Offering up to 4,264,532 common shares for up to 14.2M warrants (0.30 per warrant).
TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility
Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.
TriSalus Life Sciences secures up to $50M debt financing from OrbiMed; $25M funded at close
$25M funded on April 30, 2024; up to $25M additional available in two tranches subject to revenue thresholds.
TriSalus dismisses KPMG, hires Grant Thornton; KPMG cited going concern
Dismissed KPMG as auditor on April 12, 2024; KPMG's reports included a going concern emphasis citing recurring losses.
TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors
Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.
TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)
Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).
TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months
Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.
Entered Standby Equity Purchase Agreement to sell up to $30M common stock to Yorkville at 96-97% of VWAP.
TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study
Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.
MedTech Acquisition shareholders approve TriSalus merger; $9.4M redeemed
All 14 proposals approved by >99% of votes cast at August 8 special meeting.
FDA requests additional dose study for TriSalus SD-101; NDA likely beyond 2025
TriSalus received FDA written responses on July 31, 2023 for PERIO-01 Type B meeting regarding SD-101 for metastatic uveal melanoma.
Special meeting for TriSalus business combination adjourned to August 8, 2023 at 11:00 a.m. ET.
MedTech Acquisition raises additional $22.3M in PIPE for TriSalus merger; amends merger agreement
Entered into subscription agreements for 2,229,500 shares of Series A Preferred at $10/share, aggregate $22,295,000.
On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.
As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medical Officer of the Company, effective June 29, 2026.
Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.
On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.
On April 20, 2025, George Kelly Martin informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately.
On April 16, 2025, Liselotte Hyveled informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of her decision to resign from her position as a member of the Board, the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of the Board, effective immediately.
On February 19, 2025, Sean Murphy notified TriSalus Life Sciences, Inc. (the “Company”) of his intent to step down as an officer and employee of the Company effective February 28, 2025.
On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.
On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.
promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company
appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer
Effective October 29, 2024, Steven Katz, M.D., the Company’s Chief Medical Officer, is no longer employed by the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material